Business Wire

IRHYTH

24.2.2021 17:02:11 CET | Business Wire | Press release

Share
New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology .

The transatlantic clinical trial found that Zio by iRhythm , an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes.

The study results lend support for Zio as a screening tool for early detection of AF. The results have important implications for stroke prevention, especially as the prevalence of AF and AF-associated strokes is increasing with the aging of the population. Zio was found to be well tolerated and effective, and the results enabled some patients to receive anticoagulant therapy (anti-clotting medication) which has the potential to avert future strokes.

“Approximately one-third of those who have AF are not aware that they have it, leaving them at a significantly elevated risk of stroke,” said Michael Coyle, CEO at iRhythm. “The clinical validation that iRhythm has seen through its recent trials – mSToPS and SCREEN-AF – demonstrates that Zio proactively identifies arrhythmias based on risk factors, helping undiagnosed populations remotely monitor their symptoms and effectively seek treatment before more serious problems can occur.”

Unlike handheld ECGs, watches, and blood pressure monitors, wearable continuous ECG devices can serve as both a screening tool and a diagnostic test, likely reducing the need for confirmatory testing. When compared with implanted cardiac monitors, wearable ECG devices are noninvasive, less costly, more accessible, and can be self-applied by patients at home.

Commenting on the news, Justin Hall, GM and VP EMEA at iRhythm said, “AF is currently the leading independent risk factor of stroke, with more than 886,000 new people being diagnosed across Europe each year. As with many heart conditions, the key to improving the outcome of AF – and therefore the associated risk of stroke – is through earlier and more accurate detection. The sooner an individual is diagnosed; the sooner medical practitioners can deploy the best course of treatment. This is something that Zio can help to achieve, even during the ongoing pandemic, through accurate, remote monitoring.”

“The big challenge is that atrial fibrillation is often a silent risk factor that can be difficult to detect with current methods,” says Dr. David Gladstone, the study’s principal investigator and stroke neurologist from Sunnybrook Health Sciences Centre and Department of Medicine in the University of Toronto Temerty Faculty of Medicine. “If we are able to better detect atrial fibrillation, then more people could receive treatment for it earlier, and more strokes ought to be prevented,” adds Dr. Gladstone, who recently presented the research findings at the World Stroke Congress.

“These results are an important step towards stroke prevention by early detection of atrial fibrillation,” said Dr. Rolf Wachter, co-principal investigator, cardiologist at the University Hospital in Leipzig, Germany and scientist at the German Center for Cardiovascular Research.

In recent months, iRhythm has also been awarded a positive recommendation from the National Institute for Health and Care Excellence (NICE), as well as being named a winner of the UK government’s AI in Health and Care Award. Both achievements – along with this most recent study – are opening the door for the Zio service to be more widely adopted within the NHS.

About the study

The study recruited 856 individuals from 48 primary care clinics between 2015 and 2019. It involved participants aged 75 years or older who had high blood pressure but no previous diagnosis of AF. Half of the participants were given Zio monitors to wear at home for up to four weeks, while the other half of participants received standard medical care. All participants were observed for six months.

Clinical collaboration was supported through Sunnybrook Health Sciences Centre, the German Center for Cardiovascular Research, the Heart Center in Göttingen, and the Population Health Research Institute.

Read the full study here .

About Atrial Fibrillation
Atrial fibrillation (AF or AFib) is a quivering or irregular heartbeat, also known as an arrhythmia, which can lead to blood clots, stroke, heart failure, and other heart-related complications. Normally, the heart contracts and relaxes to a regular beat. In AF, the upper chambers of the heart (the atria) beat irregularly instead of beating effectively to move blood into the ventricles.
AF is associated with up to a five-fold increase1 in the risk of stroke, with these strokes tending to be severe and often associated with high mortality. However, approximately one-third2 of those who have AF are not aware that they have it.

For many individuals who experience a stroke due to AF, the occurrence of AF was not diagnosed until the time of their stroke or shortly afterward. Asymptomatic or undiagnosed AF is referred to as being “silent” and there are certain risk factors like aging and high blood pressure that increase an individual’s likelihood of developing it.

About the SCREEN-AF Study
SCREEN-AF was an investigator-initiated and investigator-led academic clinical trial that evaluated home-based atrial fibrillation screening in older primary care patients with hypertension. A wearable cECG strategy for up to four weeks detected a substantial prevalence (5%) of subclinical AF, was superior to six months of standard clinical care for AF detection, and resulted in more patients prescribed anticoagulant medication for stroke prevention. Most AF cases were paroxysmal, with episodes lasting many hours. Patient adherence to cECG was high; three-quarters of AF cases were detected within the first two weeks of ECG monitoring, and 90% of cases would have been missed using a 24-hour Holter monitor alone.

ClinicalTrials.gov Identifier: NCT02392754

About iRhythm Technologies, Inc.
iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterisation have the potential to change the clinical management of patients.


1 lf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.
2 iberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release

The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F

Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 13:00:00 CET | Press release

32 webstore sizes ship in 48 hours, with custom sizes from 0.010" to 0.400" ID built in 2–3 weeks Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye